Parkinson’s disease (PD) remains a significant challenge in neurodegenerative research, with the GBA1 mutation presenting a particularly aggressive form of the disease. Gain Therapeutics is making significant strides in the treatment of GBA1 Parkinson’s disease (GBA1-PD) with its lead drug candidate, GT-02287. This innovative therapy is currently in Phase 1 clinical development and has shown promising results in preclinical models, particularly in improving activities of daily living and cognitive performance.

 Understanding GT-02287

GT-02287 is an orally bioavailable, brain-penetrant small molecule that acts as a structurally targeted allosteric regulator. It binds to glucocerebrosidase (GCase), stabilizing and enhancing its function by chaperoning it to the lysosome. This mechanism is crucial for addressing the root causes of GBA1-PD, where mutations in the GBA1 gene lead to reduced GCase activity, causing the accumulation of toxic proteins like alpha-synuclein.

The Gain Therapeutics team presented the below abstract at the FENS Forum in June 2024.

 

The Objective: Restoring Daily Function and Cognition

The primary objective of this study was to investigate the potential of GT-02287 to improve nest-building behavior—a key indicator of daily living activities and cognitive function—in a mouse model of GBA1-Parkinson's disease (GBA1-PD). This preclinical trial sought to determine whether delayed administration of GT-02287 could reverse deficits in these areas.

Methodology and Results

In the study, C57BL/6 mice were injected with alpha-synuclein preformed fibrils (PFFs) to induce Parkinsonian symptoms. Additionally, a group of mice received chronic intraperitoneal administration of conduritol beta-epoxide (CBE), an irreversible GCase inhibitor, to further model GBA1-PD. GT-02287 was administered orally once daily, starting eight days after the initial exposure to the toxic agents.

Nest-building performance was carefully assessed by scoring the quality of nests built by the mice, alongside testing motor function through the wire hang test. Biomarkers of neurodegeneration, such as plasma neurofilament light chain (NfL) levels, were measured using ELISA, while immunohistochemistry was employed to quantify levels of aggregated alpha-synuclein, Iba-1 (a marker of microgliosis), and GFAP (a marker of astrogliosis).

Conclusion: A Promising Future for GT-02287

The findings underscore GT-02287's potential as a disease-modifying therapy for GBA1-PD, offering improvements in cognitive function and daily living activities. As Gain Therapeutics moves forward with clinical trials, there is optimism about the drug's ability to slow or halt the progression of Parkinson’s disease, particularly in addressing the cognitive decline associated with GBA1 mutations.

 

Gain Therapeutics continues to leverage its innovative Magellan™ platform, utilizing AI-supported structural biology and supercomputer-powered models to discover novel allosteric binding sites. This approach not only enhances the potential of GT-02287 but also opens new avenues for treating complex neurodegenerative diseases.

 

Latest Articles